In the Original Investigation titled 鈥淓valuation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,鈥�1 published online May 29, 2018, there was an error in Table 1. In the 14th row of the table, 鈥淧atients with acute medication overuse,鈥� the number and percentage values should read 鈥�87 (20.2)鈥� for the Placebo column; 鈥�39 (18.3)鈥� for the Galcanezumab, 120 mg, column; and 鈥�42 (19.8)鈥� for the Galcanezumab, 240 mg, column. This article was corrected online.
1.Stauffer
聽VL, Dodick
聽DW, Zhang
聽Q, Carter
聽JN, Ailani
聽J, Conley
聽RR. 聽Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.聽聽JAMA Neurol. 2018;75(9):1080-1088.